Drug Trial Radar · NCT07679893
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
May 15, 2026
Primary completion
Dec 30, 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Mannkind CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg BID, 4 mg BID, or matching placebo for 12 weeks, followed by a 24-week open-label extension in which all participants receive active treatment. The primary focus is on safety-particularly bronchospasm events, lung function changes (FEV1, FEV1/FVC), and adverse event rates and assessing the effectiveness of nintedanib DPI in treating IPF.
Conditions
- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Nintedanib Dry Powder InhalationDrug
Nintedanib DPI is a dry powder nintedanib formulation for oral inhalation.
PlaceboDrug
Placebo oral inhalation powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and EfficacyTime frame: From enrollment to the end of randomized treatment at 12 weeks
- Events of clinical bronchospasmTime frame: From enrollment to the end of open-label treatment at 36 weeks
- FEV1 changeTime frame: From enrollment to the end of open-label treatment at 36 weeks
- Spirometry ChangeTime frame: enrollment to end of open label at 36 weeks
- Study Drug DiscontinuationTime frame: From enrollment to the end of open-label treatment at 36 weeks
- Study Drug Dose ReductionsTime frame: From enrollment to the end of open-label treatment at 36 weeks
- Adverse EventsTime frame: From enrollment to the end of open-label treatment at 36 weeks
- Related Adverse EventsTime frame: From enrollment to the end of open-label treatment at 36 weeks
- Serious Adverse EventsTime frame: From enrollment to the end of open-label treatment at 36 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Trial Management Group Inc
Windsor, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.